Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

MLTX

$11.472.63%-0.31

Moonlake Immunotherapeutics (MLTX)

Date: O: H: L: C: Vol:

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - GlobeNewswire Inc.

(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near - Yahoo Finance

MoonLake Immunotherapeutics advances sonelokima... - Pluang

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy - Seeking Alpha

GOOG: Alphabet Inc - Ordinary Shares - Class C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Deep Track Capital, LP Expands MoonLake Immunotherapeutics (MLTX) Stake With 1.59 Million Share Purchase - GuruFocus

MoonLake (MLTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark in the Available Record; Closing Move - Vinanet

Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review

Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review

MoonLake (MLTX) Financial Results: EPS Does Not Reach the Reported Estimate; After Results: Shares Finish 5.97% Lower on the Day - Earnings Recovery Stocks - vinanet.vn

Class Action Alert: Levi & Korsinsky Reminds MoonLake (MLTX) Investors of December 15, 2025 Deadline - The National Law Review

MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits

Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX - marketbeat.com

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake - stocktitan.net

T. Rowe Price (MLTX holder) discloses 5.3% MoonLake Immunotherapeutics position - Stock Titan

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A - Stock Titan

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50 - Moomoo

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital - The Globe and Mail

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail

MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunother - The National Law Review

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study - Sahm

Avoiding Lag: Real-Time Signals in (MLTX) Movement - Stock Traders Daily

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% - Time to Sell? - MarketBeat

MoonLake’s Sonelokimab Meets Primary Endpoint in Phase 3 PsA Trial - The Dermatology Digest

MoonLake’s nanobody boosts PsA indication hopes after Phase III success - Yahoo

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail

MoonLake’s nanobody boosts PsA indication hopes after Phase III success - Clinical Trials Arena

A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34 - Moomoo

MoonLake's nanobody clears Phase III test, but shares slip - The Pharma Letter

MoonLake Immunotherapeutics (MLTX) Stock Analysis: 61% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews

Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? - STAT

How Psoriatic Arthritis Trial Success and Q2 Losses Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st

MoonLake touts Phase III PsA data, but investors may have wanted more - FirstWord Pharma

Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed - TradingView

Why is MoonLake Immunotherapeutics stock plunging today? By Investing.com - Investing.com India

MoonLake Immunotherapeutics Releases Q2 2026 Financial Results - AlphaStreet

What's Going On With MoonLake Stock Monday? - MoonLake (NASDAQ:MLTX) - Benzinga

MoonLake's sonelokimab meets all endpoints in Phase 3 IZAR-1 psoriatic arthritis trial - Dealroom

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down - Here's What Happened - MarketBeat

Moomoo AI Day 7 (Aug'26) - Moonlake Immunotherapeutic (MLTX.US) R&D expenses and cash on hand - Moomoo

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News

Traders Buy Large Volume of MoonLake Immunotherapeutics Call Options (NASDAQ:MLTX) - MarketBeat

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce Biotech

Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial - dermatologytimes.com

MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves - Kalkine Media

MoonLake Immunotherapeutics Announces Q2 2026 Financial Results and Positive Phase 3 IZAR-1 Trial Data for Sonelokimab in Psoriatic Arthritis - Kalkine Media

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Yahoo Finance

Simile a MLTX

CGEM$14.930.67%

RIGL$50.531.52%

ODTX$19.530.05%

GLUE$10.631.21%